TNFRSF9 and ovarian carcinoma: Importantly, addition to the anti-PD-1/CD137 mAb combination of cisplatin, a commonly used chemotherapeutic drug for the treatment of ovarian cancer [43], administered at a dose equivalent to those used clinically [38], provided long term remission (most likely cure) in 80% of the treated mice and induced a systemic memory immune response which was antigen specific.